Nirmatrelvir Plus Ritonavir Reduces Risks for COVID-19 in Seniors
MONDAY, Dec. 12, 2022 (HealthDay News) — Nirmatrelvir plus ritonavir reduces the risk for hospitalization or death after an outpatient diagnosis of COVID-19 among older adults, according to a study published online Dec. 13 in the Annals of Internal M…
Learn MoreU.S. Health Officials Urge Indoor Masking in Major Cities as ‘Tripledemic’ Rages
MONDAY, Dec. 12, 2022 (HealthDay News) – As three highly contagious respiratory viruses spread across the United States, straining hospitals and triggering drug shortages, health officials in some major cities and states are calling for a return to in…
Learn MoreLa FDA aprueba los refuerzos bivalentes contra la COVID para los niños de a partir de 6 meses
JUEVES, 8 de diciembre de 2022 (HealthDay News) — Los refuerzos bivalentes actualizados contra la COVID-19 cuentan ahora con la aprobación para su uso en niños de incluso apenas 6 meses, anunció hoy la Administración de Alimentos y Medicamentos (FDA)…
Learn MoreViral Rebound Uncommon After Molnupiravir, Nirmatrelvir-Ritonavir Therapy
FRIDAY, Dec. 9, 2022 (HealthDay News) — Patients with COVID-19 taking molnupiravir or nirmatrelvir-ritonavir rarely have viral rebound, and rebound is not associated with increased mortality risk, according to a study published online Dec. 6 in JAMA …
Learn MoreHalf of U.S. Adults Not Concerned About the Flu
FRIDAY, Dec. 9, 2022 (HealthDay News) — More than half of U.S. adults say they are not very or not at all concerned about the upcoming flu season, according to the results of a survey released Nov. 29 by the American Heart Association.The online surv…
Learn MorePaxlovid Safe for Pregnant Patients With COVID-19
FRIDAY, Dec. 9, 2022 (HealthDay News) — Pregnant patients treated with nirmatrelvir and ritonavir (Paxlovid) for COVID-19 tolerate the treatment well, according to a study published online Nov. 29 in JAMA Network Open.William M. Garneau, M.D., from t…
Learn MoreJYNNEOS Vaccination Provides Protection Against Mpox
THURSDAY, Dec. 8, 2022 (HealthDay News) — Among men aged 18 to 49 years who are eligible for the JYNNEOS vaccine, mpox incidence is considerably higher among unvaccinated persons versus those who received one or two vaccine doses, according to resea…
Learn MoreMost Common Adverse Events With JYNNEOS Are Nonserious
THURSDAY, Dec. 8, 2022 (HealthDay News) — The JYNNEOS vaccine, which is recommended for persons exposed to or at high risk for exposure to mpox virus, seems safe, with the most common adverse health events reported as nonserious, according to resear…
Learn MoreFDA Approves Bivalent COVID-19 Boosters for Children 6 Months and Older
THURSDAY, Dec. 8, 2022 (HealthDay News) — The updated bivalent COVID-19 boosters are now approved for use in children as young as 6 months of age, the U.S. Food and Drug Administration announced today.Children can receive either a Moderna or Pfizer-B…
Learn MorePaxlovid pronto no será gratuito para los estadounidenses
MIÉRCOLES, 7 de diciembre de 2022 (HealthDay News) — El antiviral Paxlovid ha evitado que las personas enfermen de gravedad y mueran por la COVID-19 desde que salió, sin ningún costo para ellas.Pero a mediados del próximo año, el gobierno de EE. UU. …
Learn More